knowledge -WSS

knowledge

author：leisure time 2025-09-28 23:49:27 - browse：363

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Lack of health data on LGBTQ+ people has serious consequences

hotspot

leisure time

focus

WSS

Readers discuss the intersection of pregnancy and addiction

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Streamlined flu vaccines recommended by FDA advisory panel

Study: Why relieving medical debt did not improve financial outcomes

IVF doctors demand details after CooperSurgical lawsuit

Statins may not be needed by millions of people, study suggests

focus

knowledge

focus

Hollywood unions extend contract negotiations for actors

Medical device trials still don't enroll enough women, study finds

Medical records are filled with copy

My daughter's legacy lives on through her writing, phage therapy

As demand for Covid shots wanes, Moderna seeks its next success

Statins may not be needed by millions of people, study suggests

In age of alternative facts, a scholarly course on calling out crap

Streamlined flu vaccines recommended by FDA advisory panel

New air purifier tech could be key to improving indoor air quality

Stem cell biologist probes earliest stages of human development

explore

Lilly's Alzheimer's drug donanemab backed by FDA advisers

State of the Union pitch: Bigger Medicare drug price negotiations

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Medicare drug price negotiation hearing pits pharma v Biden admin

Ozempic has benefits for kidney disease as well as diabetes

He's 19 months old and has one of the world’s rarest diseases

hotspot

leisure time

focus

focus